Evidence map›Paper›PMID 26413339›Full record

ReviewArab journal of urology2015

Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review.

Albert Haddad, Michel Jabbour, Muhammad Bulbul

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Arab journal of urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Albert HaddadLilly Research Laboratories, Eli Lilly and Company, Dubai, United Arab Emirates.
Michel JabbourDivision of Urology, Saint Georges Hospital, Balamand University, Achrafieh, Beirut, Lebanon.
Muhammad BulbulDivision of Urology, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon.
American University of Beirut Medical Center · LB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many men have coexistent erectile dysfunction (ED) and lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH). Phosphodiesterase type 5 (PDE5) inhibitors are effective for treating both of these conditions independently. In this review we summarise the evidence supporting a link between ED and LUTS/BPH, and the results from key clinical studies related to the use of PDE5 inhibitors for treating both conditions. The results from these studies suggest that men who have both ED and LUTS/BPH, and are concerned about their sexual dysfunction, might benefit from single-agent, holistic treatment with a PDE5 inhibitor.

Indexed as

5ARI, 5α-reductase inhibitorAE, adverse eventBenign prostatic hyperplasiacGMP, cyclic guanosine monophosphateED, erectile dysfunctionEF, erectile function (domain)Erectile dysfunctionIIEF, International Index of Erectile FunctionLUTSNO, nitric oxidePDE5 inhibitorPDE5, phosphodiesterase type 5QoL, quality of lifeRhoA, Ras homologue gene family member AROCK, Rho-associated protein kinase

Identifiers

PMID26413339
PMCPMC4563010
OpenAlexW842621837

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.